Thu.Nov 07, 2024

article thumbnail

GLP-1s Are At the Forefront, but Other Obesity Treatments Exist

Pharmacy Times

In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.

149
149
article thumbnail

These 6 companies are using AI to streamline clinical trials for pharma

STAT

In the last year, drugmakers have talked up the prospect of medicines discovered or designed by artificial intelligence.

138
138
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Implementation of Supply-Related Restrictive Measures Reduces IVIG Use

Pharmacy Times

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

144
144
article thumbnail

Quest Diagnostics expands network partnership with Anthem plans

Fierce Healthcare

Quest Diagnostics and Elevance Health are broadening their partnership into four more states with the goal of making it easier for patients to access in-network laboratory services. | Quest Diagnostics and Elevance Health are broadening their partnership into four more states, with the goal of making it easier for patients to access in-network laboratory services.

128
128
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Risk of Developing Eosinophilic Esophagitis Is Higher in Pediatric Patients With Atopic Conditions

Pharmacy Times

Children with certain atopic conditions, including asthma and common food allergies, were observed to have a higher risk of developing the chronic disorder.

139
139
article thumbnail

General Catalyst's HATCo moves forward on $485M Summa Health deal

Fierce Healthcare

Venture capital firm General Catalyst's Health Assurance Transformation Corporation (HATCo) signed a definitive agreement to buy Summa Health for $485 million, the organizations announced Thursday. | Venture capital firm General Catalyst's Health Assurance Transformation Corporation signed a definitive agreement to buy Summa Health for $485 million, the organizations announced Thursday.

126
126

More Trending

article thumbnail

Sarepta pulls plug on Duchenne exon-skipping drug

pharmaphorum

Sarepta has halted development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy therapy Exondys 51.

115
115
article thumbnail

FDA Proposes Removal of OTC Oral Phenylephrine From Cough/Cold Products

Pharmacy Times

Evidence shows that the agent is not an effective nasal decongestant.

FDA 117
article thumbnail

Gastrointestinal Stromal Tumors Increased in Past 20 Years

Drug Topics

Researchers attempted to understand the evolving epidemiology of gastrointestinal stromal tumors in major organ sites.

112
112
article thumbnail

More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce

Fierce Pharma

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. | After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring, cutting the autoimmune disease biotech's workforce for a second time in less than a year.

111
111
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Q&A: Pharmacists Champion Nonopioid Pain Management Strategies

Drug Topics

Melissa Durham, PharmD, MACM, reveals how pharmacists are uniquely positioned to counsel patients on nonopioid pain management.

112
112
article thumbnail

Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

Fierce Pharma

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its bread-and-butter antirival franchise with an eye on the potential of its long-acting | Gilead's CAR-T therapies Yescarta and Tecartus have stayed relatively flat all year with its Yescarta facing a 1% decline over the third quarter due to competition.

111
111
article thumbnail

Webinar recap: Boosting recruitment and retention with SDOH data

pharmaphorum

Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.

111
111
article thumbnail

Lerodalcibep Delivers Significant LDL-C Reduction for High-Risk Cardiovascular Patients

Pharmacy Times

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

107
107
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Avid Bioservices to go private in $1.1bn private equity deal

pharmaphorum

Nasdaq-listed CDMO Avid Bioservices has agreed a $1.

110
110
article thumbnail

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

Pharmaceutical Technology

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

105
105
article thumbnail

Blueprint's mastocytosis drug Ayvakit cleared for NHS use

pharmaphorum

NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis

105
105
article thumbnail

Researchers Highlight Need for Increased RSV Vaccination

Pharmacy Times

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Vaccines 101
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Minister for Science champions partnerships with private clinical sector in UK

Pharmaceutical Technology

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

98
article thumbnail

Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales

Fierce Pharma

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the gene therapy. | An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy Elevidys has sparked a new surge in sales. The gene therapy's $181 million sales in the third quarter beat analysts' expectations as it made a 48% sequential leap.

FDA 98
article thumbnail

Aditum Bio and Leads Biolabs Form New Company, Oblenio Bio, for Developing a Therapeutic Antibody to Treat Autoimmune Disorders

BioPharm

Under an agreement, Leads Biolabs has granted the new company, Oblenio Bio, an exclusive option to license LBL-051, a tri-specific T-cell engager antibody.

98
article thumbnail

DBV Technologies’ stock slides as financial woes worsens

Pharmaceutical Technology

The company reported that it does not have sufficient cash reserves to operate for the next 12 months, can only fund operations into Q1 2025.

98
article thumbnail

Metrics for the UK’s VPAG: A work in progress

pharmaphorum

Discover the latest metrics and updates on the UK's VPAG (Voluntary scheme for branded medicines Pricing, Access and Growth) from NICE (National Institute for Health and Care Excellence). Stay informed on this work in progress.

97
article thumbnail

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

Fierce Pharma

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. But the Massachusetts biotech's RSV shot fell way short of expectations.

article thumbnail

Addressing Racial Disparities in Opioid Prescriptions: The Role of Pharmacists in Achieving Equity

Pharmacy Times

Pharmacists, who play a crucial role at the intersection of prescribing and dispensing, are well-positioned to influence these disparities.

94
article thumbnail

Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist

Outsourcing Pharma

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

93
article thumbnail

CerpassRx, Waltz Health team up to bring down specialty pharmacy costs

Fierce Healthcare

CerpassRx, an independent pharmacy benefit manager, is teaming up with Waltz Health to launch a new AI-powered tool that aims to better manage specialty drug spending. | CerpassRx, an independent pharmacy benefit manager, is teaming up with Waltz Health to launch a new AI-powered tool that aims to better manage specialty drug spending.

article thumbnail

Q&A: Key Things Pharmacists Need to Know About Insulin Icodec

Drug Topics

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses a recent meta-analysis that evaluated the efficacy, safety, and clinical implications of insulin icodec.

76
article thumbnail

CHAI members hash out remaining questions about AI assurance labs

Fierce Healthcare

At the Coalition for Health AI’s Global Summit in Las Vegas, CHAI members gathered to tease out some of the most basic questions about their proposed national network of AI assurance labs | At the CHAI Global Summit in Las Vegas in October, CHAI members openly debated about who would use the assurance labs and who would pay for model validation, among other fundamental questions.

81
article thumbnail

Senhwa Biosciences starts trial of silmitasertib in children with difficult to treat cancers

Outsourcing Pharma

The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.

75
article thumbnail

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

PharmaVoice

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.

74
article thumbnail

NeueHealth shows off ‘strongest’ earnings performance but profitability lags

Fierce Healthcare

NeueHealth CEO Mike Mikan began the company’s extremely quick third quarter earnings call highlighting the “strongest financial performance to date,” seemingly boosting its stock Oct. 7. | NeueHealth posted another quarterly net loss as the company tries to dig itself out of a huge hole.

72
article thumbnail

Healthcare Email Marketing Strategies: A Guide for Pharma Executives

Pharma Marketing Network

In today’s digital world, healthcare email marketing is more than just sending out newsletters. It’s a strategic tool that, when done right, can boost engagement, nurture relationships with healthcare professionals (HCPs), and increase brand awareness. But how can pharma companies truly maximize the potential of email marketing? Let’s dive in and explore some proven strategies.

HIPAA 52